The diabetes market is expected to reach a massively big €86Bn by 2025 combining both type 1 (€32Bn) and type 2 (€54Bn) treatments, and we can expect all sort of revolutionary technologies to come forward and claim their market share. Researchers are already speculating about microchips that can diagnose diabetes type 1 before the symptoms appear or nanorobots traveling in the bloodstream while they measure glucose and deliver insulin.
Maddy Arnstein has lived with T1D for over 50 years. She became involved with JDRF when she saw the dramatic difference technologies like the insulin pump could have on her life. Maddy was quickly drawn to advocacy—initially to help secure continued renewal of funding for the Special Diabetes Program (SDP). But once she started using a continuous glucose monitor, she dedicated herself to fighting for Medicare coverage.
Sandi takes several medications for diabetes, asthma, and kidney damage, and she says one source of anxiety is the feeling that she can never get her diabetes under control. Recently, when she had to switch her asthma medication, her fasting blood glucose levels skyrocketed from between 85 and 100 milligrams per deciliter (mg/dl) to between 160 and 180 mg/dl. It took two months to bring them back down, but they were still not stabilized.